NYSE:LLYPharmaceuticals
Eli Lilly (LLY) Valuation Check After Breakthrough Therapy Status For Sofetabart Mipitecan
The FDA’s Breakthrough Therapy designation for Eli Lilly (LLY) candidate sofetabart mipitecan in platinum resistant ovarian cancer has pushed oncology back into focus for a stock many investors mainly associate with obesity drugs.
See our latest analysis for Eli Lilly.
The Breakthrough Therapy news lands after a busy start to the year for Eli Lilly, with an AI co-innovation lab launched alongside NVIDIA, new distribution for its obesity medicines through CenterWell Pharmacy, and fresh legal...